Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 1451 to 1500 of 3761 results for treatment

  1. Photodynamic therapy for localised inoperable endobronchial cancer (HTG85)

    Evidence-based recommendations on photodynamic therapy (PDT) for localised inoperable endobronchial cancer (non-small-cell lung cancer). This involves injecting a photosensitising agent into the body that is activated by laser light to destroy the cancerous tissue.

  2. Acute kidney injury (QS76)

    This quality standard covers preventing, detecting and managing acute kidney injury in adults, young people and children. It describes high-quality care in priority areas for improvement.

  3. Low-level laser therapy for preventing or treating oral mucositis caused by radiotherapy or chemotherapy (HTG472)

    Evidence-based recommendations on low-level laser therapy for preventing or treating oral mucositis caused by radiotherapy or chemotherapy. This involves applying low-energy lasers to the affected tissue.

  4. Micropressure therapy for refractory Ménière's disease (HTG285)

    Evidence-based recommendations on micropressure therapy for refractory Ménière's disease. This involves inserting a grommet (small tube) through the eardrum into the middle ear and blowing air at low pressure into the inner ear.

  5. How effective is stereotactic ablative radiotherapy compared with standard radiotherapy in the postoperative treatment of metastatic spinal cord compression (MSCC)?

    radiotherapy compared with standard radiotherapy in the postoperative treatment of metastatic spinal cord compression (MSCC)? Any...

  6. What is the effectiveness and safety of extended pharmacological venous thromboembolism (VTE) prophylaxis for people who have been discharged after treatment for COVID-19?

    thromboembolism (VTE) prophylaxis for people who have been discharged after treatment for COVID-19? Any explanatory notes(if applicable)...

  7. Liraglutide for managing overweight and obesity (TA664)

    Evidence-based recommendations on liraglutide (Saxenda) for managing overweight and obesity alongside a reduced-calorie diet and increased physical activity in adults.

  8. Digital therapy for chronic tic disorders and Tourette syndrome: early value assessment (HTG748)

    Early value assessment (EVA) guidance on digital therapy for chronic tic disorders and Tourette syndrome.

  9. Antimicrobial prescribing: oritavancin for acute bacterial skin and skin structure infections (ES39)

    Summary of the evidence on oritavancin for acute bacterial skin and skin structure infections (ABSSSI) in adults

  10. Transcranial magnetic stimulation for auditory hallucinations (HTG555)

    Evidence-based recommendations on transcranial magnetic stimulation for auditory hallucinations. This involves stimulating the brain with pulses of electromagnetic energy.

  11. Information and support: How does each step in the care pathway for prevention and treatment of early-onset neonatal infection impact on babies and their families?

    and support: How does each step in the care pathway for prevention and treatment of early-onset neonatal infection impact on babies and...

  12. Automated ankle brachial pressure index measurement devices to detect peripheral arterial disease in people with leg ulcers (HTG677)

    Evidence-based recommendations on automated ankle brachial pressure index measurement devices to detect peripheral arterial disease in people with leg ulcers.

  13. Oral health promotion: general dental practice (NG30)

    This guideline covers how general dental practice teams can convey advice about oral hygiene and the use of fluoride. It also covers diet, smoking, smokeless tobacco and alcohol intake.

  14. Focal therapy using cryoablation for localised prostate cancer (HTG284)

    Evidence-based recommendations on focal therapy using cryoablation for localised stage prostate cancer. This involves using freezing (cryotherapy) needles to find and destroy only the cancerous part of the prostate.

  15. Drainage, irrigation and fibrinolytic therapy (DRIFT) for post-haemorrhagic hydrocephalus in preterm infants (HTG276)

    Evidence-based recommendations on drainage, irrigation and fibrinolytic therapy (DRIFT) for post-haemorrhagic hydrocephalus in preterm infants. This involves draining excess CSF from the brain, washing out the blood, and breaking down blood clots using drugs (fibrinolytics).

  16. Type 2 diabetes: insulin degludec/liraglutide (Xultophy) (ESNM60)

    Summary of the evidence on insulin degludec/liraglutide (Xultophy) for treating type 2 diabetes to inform local NHS planning and decision-making

  17. Postural hypotension in adults: fludrocortisone (ESUOM20)

    Summary of the evidence on fludrocortisone for treating postural hypotension in adults to inform local NHS planning and decision-making

  18. Peripheral arterial disease (QS52)

    This quality standard covers diagnosing and managing lower limb peripheral arterial disease in adults (aged 18 and over). It describes high-quality care in priority areas for improvement.

  19. EXOGEN ultrasound bone healing system for long bone fractures with non-union or delayed healing (HTG296)

    Evidence-based recommendations on EXOGEN ultrasound bone healing system for long bone fractures with non-union or delayed healing.

  20. Magnetic resonance therapy for knee osteoarthritis (HTG588)

    Evidence-based recommendations on magnetic resonance therapy for knee osteoarthritis in adults. This involves placing a magnetic resonance device over the knee to stimulate cartilage to heal and relieve the symptoms of osteoarthritis.

  21. Extracorporeal shockwave therapy for calcific tendinopathy in the shoulder (HTG645)

    Evidence-based recommendations on extracorporeal shockwave therapy for calcific tendinopathy in the shoulder. This involves placing a device on the skin that delivers short pulses of sound into the shoulder. The aim is to reduce pain and improve shoulder function.

  22. Cefiderocol for treating severe drug-resistant gram-negative bacterial infections (AMR2)

    Evidence-based recommendations on cefiderocol for treating severe drug-resistant gram-negative bacterial infections.

  23. What is the effectiveness of laparoscopic fundoplication compared with medical management in people with GORD that does not respond to optimal proton pump inhibitor (PPI) treatment?

    with GORD that does not respond to optimal proton pump inhibitor (PPI) treatment? Any explanatory notes(if applicable) Current evidence...

  24. Extracorporeal albumin dialysis for acute liver failure (HTG202)

    Evidence-based recommendations on extracorporeal albumin dialysis for acute liver failure. This involves using a dialysis machine to remove both water-soluble toxins and toxins that are attached to albumin and accumulate in liver failure.

  25. Image-guided percutaneous laser ablation for primary and secondary liver tumours (HTG722)

    Evidence-based recommendations on image-guided percutaneous laser ablation for primary and secondary liver tumours. This involves heating up liver tissue to destroy tumours.

  26. Remsima (infliximab biosimilar) for subcutaneous injection for managing Crohn's disease and ulcerative colitis (ES35)

    Summary of the evidence on remsima (infliximab biosimilar) for subcutaneous injection for managing Crohn’s disease and ulcerative colitis

  27. Ceftazidime with avibactam for treating severe drug-resistant gram-negative bacterial infections (AMR1)

    Evidence-based recommendations on ceftazidime with avibactam for treating severe drug-resistant gram-negative bacterial infections.

  28. Transcranial magnetic stimulation for treating and preventing migraine (HTG330)

    Evidence-based recommendations on transcranial magnetic stimulation for treating and preventing migraine. This involves placing a handheld device on the scalp to deliver magnetic pulses to the head.

  29. Tafasitamab with lenalidomide and rituximab for treating relapsed or refractory follicular lymphoma after 1 or more systemic treatments ID6413

    In development Reference number: GID-TA11488 Expected publication date:  15 July 2026

  30. Antimicrobial prescribing: eravacycline for complicated intra-abdominal infections in adults (ES40)

    Summary of the evidence on eravacycline for complicated intra-abdominal infections in adults

  31. Extracorporeal shockwave therapy for Achilles tendinopathy (HTG426)

    Evidence-based recommendations on extracorporeal shockwave therapy for treating Achilles tendinopathy in adults. This involves passing shockwaves through the skin to the affected area.

  32. What is the efficacy and cost effectiveness of rehabilitation services compared with treatment as usual for people with complex psychosis with residual disability, who are leaving early intervention services?

    efficacy and cost effectiveness of rehabilitation services compared with treatment as usual for people with complex psychosis with...

  33. Cemiplimab for adjuvant treatment of high-risk cutaneous squamous cell carcinoma after surgery and radiotherapy [ID6659]: consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators

    We are listening to your views on this Technology appraisal guidance. Comments close 19 February 2026.

  34. Intralesional photocoagulation of subcutaneous congenital vascular disorders (HTG56)

    Evidence-based recommendations on intralesional photocoagulation of subcutaneous congenital vascular disorders. This involves inserting a laser fibre into the lesion to deliver the light deep within it.

  35. Minimally invasive video-assisted thyroidectomy (HTG349)

    Evidence-based recommendations on minimally invasive video-assisted thyroidectomy. This involves inserting instruments through a small cut (keyhole surgery) to remove part or all of the gland.

  36. Electrically stimulated intravesical chemotherapy for non-muscle-invasive bladder cancer (HTG499)

    Evidence-based recommendations on electrically stimulated intravesical chemotherapy for non-muscle-invasive bladder cancer in adults. This involves using a small electrical current to improve the effect of chemotherapy given directly into the bladder.

  37. Bronchial thermoplasty for severe asthma (HTG494)

    Evidence-based recommendations on bronchial thermoplasty for severe asthma in adults. This involves applying heat to the inside walls of the airways.

  38. Controlled drugs: safe use and management (NG46)

    This guideline covers systems and processes for using and managing controlled drugs safely in all NHS settings except care homes. It aims to improve working practices to comply with legislation and have robust governance arrangements. It also aims to reduce the safety risks associated with controlled drugs.

  39. Percutaneous laser therapy for fetal tumours (HTG118)

    Evidence-based recommendations on percutaneous laser therapy for fetal tumours. This involves inserting a needle through the mother's abdomen to the tumour and using laser energy to shrink it.

  40. Treatment for people with an IOP of 22 or 23 mmHg:- What is the clinical and cost effectiveness of treating an intraocular pressure (IOP) of 22 or 23 mmHg in people with normal optic discs and visual fields?

    Recommendation ID NG81/6 Question Treatment for people with an IOP of 22 or 23 mmHg:- What is the clinical and cost effectiveness of...

  41. Chronic anal fissure: botulinum toxin type A injection (ESUOM14)

    Summary of the evidence on botulinum toxin type A injection for treating chronic anal fissure to inform local NHS planning and decision-making

  42. About interventional procedures guidance

    We assess the efficacy and safety of interventional procedures used for treatment or diagnosis to determine whether they work well enough and are safe enough for use in the NHS.

  43. Axonics sacral neuromodulation system for treating refractory overactive bladder (HTG554)

    Evidence-based recommendations on Axonics sacral neuromodulation system for treating refractory overactive bladder.

  44. Rezum for treating lower urinary tract symptoms secondary to benign prostatic hyperplasia (HTG545)

    Evidence-based recommendations on Rezum for treating lower urinary tract symptoms secondary to benign prostatic hyperplasia.

  45. Skin involvement in systemic sclerosis: rituximab (ES7)

    Summary of the evidence on rituximab (MabThera) for treating skin involvement in systemic sclerosis to inform local NHS planning and decision-making

  46. Hip fracture: management (CG124)

    This guideline covers managing hip fracture in adults. It aims to improve care from the time people aged 18 and over are admitted to hospital through to when they return to the community. Recommendations emphasise the importance of early surgery and coordinating care through a multidisciplinary Hip Fracture Programme to help people recover faster and regain their mobility.

  47. CaRi-Heart for predicting cardiac risk in suspected coronary artery disease: early value assessment (HTG663)

    Early value assessment (EVA) guidance on CaRi-Heart for predicting cardiac risk in suspected coronary artery disease.